Common questions about Cresemba (FAQ)
Q: Can Cresemba be taken with vitamins or herbal supplements?
A: Official documents state that Cresemba should not be used with strong CYP3A4/5 inducers. This group includes the herbal supplement St. John’s wort, which is strictly forbidden. Regulatory information indicates the importance of discussing all supplements with a healthcare provider, as potential drug interactions, including with strong enzyme inducers, must be managed.
Q: Is Cresemba safe for older patients?
A: Cresemba is approved for use in adults, and official regulatory information indicates that the dose is generally consistent across adult patient groups. No specific dose adjustment based solely on age is noted in the official guidance for the general elderly population. Dosing for adult patients, including older individuals, is determined by a healthcare professional based on the specific infection and patient characteristics.
Q: How is Cresemba different from other antifungal medications?
A: Cresemba is classified as a next-generation triazole antifungal. A key formulation difference is that its intravenous preparation does not require the use of cyclodextrin, which can be important for patients with reduced kidney function. Clinical studies have also shown its effect for invasive aspergillosis to be comparable to other antifungals like voriconazole.
Q: Are there any specific foods I should avoid while on Cresemba?
A: Official guidance states that the oral capsules may be taken with or without food. There are no specific foods listed in the product information that patients are required to avoid while taking this medication.
Q: What are the signs of a serious allergic reaction to Cresemba?
A: Official documentation notes that serious hypersensitivity reactions are possible, which may include symptoms such as low blood pressure, severe rash, or difficulty breathing. Official guidance states that infusion-related reactions may require the healthcare professional to stop the infusion if symptoms arise during administration.
Q: Does Cresemba affect blood pressure?
A: Low blood pressure, also known as hypotension, has been reported as an infusion-related reaction during the intravenous administration of Cresemba. Due to the potential for hypotension, monitoring of vital signs may be part of the care plan during intravenous administration.
Q: What official warnings are associated with Cresemba?
A: Official warnings include the potential for serious hepatic (liver) reactions and severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome. Monitoring of liver function tests is described in the regulatory information as a necessary measure due to the potential for hepatic reactions.
Q: Can patients with a history of heart problems use Cresemba?
A: Cresemba is contraindicated (must not be used) in patients with known Familial Short QT Syndrome because the drug is known to shorten the QTc interval. It is important that patients disclose any history of abnormal heart rate or rhythm to their prescribing doctor, as this information is crucial for safety screening against the specified contraindication.
Q: Is Cresemba used to prevent infections?
A: The official approved indication for Cresemba is the treatment of invasive aspergillosis and invasive mucormycosis. While its primary use is treatment, official studies have also examined its use in patients deemed likely to benefit from prophylaxis (prevention) intervention.
Q: How does Cresemba compare to voriconazole in terms of general use?
A: In clinical studies examining invasive aspergillosis, the observed measurements of all-cause mortality for Cresemba were found to be comparable to those observed for voriconazole. Regulatory reviews also noted that Cresemba may have advantages related to its use in patients with reduced kidney function.
Q: How quickly does Cresemba start to work?
A: Pharmacokinetic data from regulatory documents shows that the active substance, isavuconazole, generally reaches its maximum concentration in the blood within 2 to 3 hours after the capsules are taken. However, the time required for a noticeable clinical response to the infection is determined by the patient's individual condition and the severity of the illness.
Q: Will taking Cresemba affect my driving ability?
A: Official safety data lists side effects such as dizziness and somnolence (drowsiness) as potential reactions, which may impact coordination. Individuals who experience these effects are cautioned against driving or operating machinery until they know how the medication affects them.
Q: How long do most people have to take Cresemba?
A: The necessary duration of treatment for an individual is based on their clinical response. Official documents state that continued treatment beyond six months requires careful consideration of the benefit-risk balance.
Q: Does Cresemba interact with birth control pills?
A: The active substance in Cresemba is a moderate inhibitor of a liver enzyme (CYP3A4) responsible for breaking down oral contraceptives. Clinical studies show that co-administration can increase the concentration of hormonal components like ethinyl estradiol and norethindrone in the body.
Q: Are there any genetic factors that affect how Cresemba works?
A: Yes, regulatory information specifies a genetic factor that affects eligibility. Cresemba is strictly contraindicated in patients with Familial Short QT Syndrome, which is an inherited problem affecting the electrical system of the heart.
Q: Is Cresemba considered a 'last resort' drug?
A: Regulatory summaries indicate that for the treatment of invasive mucormycosis, Cresemba is used when the existing first-line treatment, amphotericin B, is considered inappropriate for the patient. For invasive aspergillosis, it is studied as a comparable option to other antifungals.
Q: What is the risk of a drug interaction with Cresemba?
A: Cresemba has a defined profile of drug interactions because it is both a substrate and moderate inhibitor of the CYP3A4/5 liver enzymes, and a mild inhibitor of P-glycoprotein. Its use is strictly contraindicated with several strong enzyme inhibitors and inducers due to the potential for dangerous changes in the drug's levels.
Q: What is the likelihood of Cresemba failing to treat the infection?
A: Clinical trials do not report general 'failure rates' but rather measured outcomes like all-cause mortality. For invasive aspergillosis, all-cause mortality at 42 days was observed to be 19% in the Cresemba treatment group. For invasive mucormycosis, the all-cause mortality was observed to be 43% at 84 days.
Q: What if I take too much Cresemba?
A: In the event of a suspected overdose, regulatory guidance for overdose specifies contacting emergency services or a poison control center for assistance. Symptoms that have been associated with taking too much of the drug include headache, dizziness, drowsiness, and numbness.
Q: Are there alternatives to Cresemba for my infection?
A: Regulatory documents mention other antifungals, such as voriconazole and amphotericin B, in the context of clinical trials and treatment justification for the approved infections. These drugs may be considered alternatives depending on the patient's condition and medical history.
Q: Can Cresemba cause changes in vision?
A: Official safety data lists decreased vision as a reported side effect, although it is typically less common. If vision changes or other eye-related symptoms are experienced, consultation with a healthcare provider is appropriate.
